How to store Oxytocin
A hormone used during childbirth; nasal social and weight-loss benefits remain unproven.
Also called: Pitocin, Syntocinon, OT, OXT, TTA-121.
Neuropeptides · Oxytocin-receptor agonist and uterotonic hormone · Evidence: Approved drug.
Comes as: Ready-to-use 10 units/mL injection solution in 1 mL single-dose vials., 10 mL multiple-dose Pitocin vials, containing 100 units total..
Mixed with: Pitocin labour infusion: 10 units in 1000 mL of 0.9% sodium chloride or lactated Ringer’s, giving 10 milliunits/mL..
- Approved injections come dissolved. For infusion, they are diluted, not mixed from powder.
- The UK product has 48-hour chemical/physical stability at 25°C after dilution; microbial limits are shorter.
- Powder-vial and home-spray mixing reports are kept in the community records, outside these label handling instructions.
Before mixing: Pitocin: 20–25°C. The checked UK ampoule: 2–8°C, protected from light; up to 30°C for 3 months, then discard.
After mixing: UK diluted infusion: use immediately; normally no longer than 24 hours at 2–8°C unless aseptic conditions are validated. This is not a home-spray shelf life.
UK Esteve oxytocin 10 IU/mL infusion ampoules: refrigerate at 2-8 C in the carton, protected from light. Use diluted infusions immediately; any delay normally must stay within 24 hours at 2-8 C unless prepared under validated sterile conditions.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- PITOCIN- oxytocin injection, Par Health USA, LLC · DailyMed · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Oxytocin 10 IU/ml Solution for infusion - Summary of Product Characteristics (SmPC), electronic medicines compendium · 2025
- Postpartum interventions to prevent postpartum haemorrhage, World Health Organization · 2025
- WHO recommendations on maternal and newborn care for a positive postnatal experience, World Health Organization · 2022
- Syntometrine, Phebra Pty Ltd · Australian Commission on Safety and Quality in Health Care · 2019
- PSUSA/00002263/201706 - periodic safety update report single assessment, EMA · 2018
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry, FDA · 2016
- Oxytocin (Aspen), Healthdirect Australia
- SYNTOCINON oxytocin 10 IU/1 mL injection ampoule (13383), Therapeutic Goods Administration
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.